non-cross-linked hyaluronic acid
ApprovedSmall molecule
non-cross-linked hyaluronic acid is one of 17 small molecule programs targeting Bursitis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Bursitis
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Aleve
Alnylam PharmaceuticalsApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Voltaren
CCerimon Pharmaceuticals
Phase 3
Experimental
BiogenPhase 2
non-cross-linked hyaluronic acid
TTaipei Medical University
Approved
MRX-7EAT
MMEDRx USA, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTaipei Medical University